Kyowa Kirin Leverages MINT Study RWE to Drive Mogamulizumab’s Market Value & Reimbursement Success
Kyowa Kirin’s MINT study shows mogamulizumab offers 60% response, 20‑month PFS and durable control, giving payers RWE‑backed value for CTCL treatment.
4 minutes to read
